Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280225 | 0.85 | EGFR (0.48) | EGFRMKNK2SOS1MKNK1SRC | |
| SCHEMBL13638737 | 0.78 | EGFR (0.42) | EGFRMKNK2PIK3CAPIK3R1SOS1 | |
| SCHEMBL3193077 | 0.75 | LRRK2 (0.41) | EGFRMKNK2PIK3CASYKMKNK1 | |
| SCHEMBL13634006 | 0.74 | SRC (0.61) | EGFRSRC | |
| SCHEMBL30817825 | 0.72 | SYK (0.47) | SYK | |
| SCHEMBL21187296 | 0.72 | SYK (0.47) | SYK | |
| SCHEMBL21178138 | 0.72 | SYK (0.47) | SYK | |
| SCHEMBL5464338 | 0.72 | CHRM4 (0.39) | — | |
| SCHEMBL18128964 | 0.71 | EGFR (0.46) | EGFRMKNK2MKNK1SRC | |
| SCHEMBL21187340 | 0.71 | IRAK4 (0.38) | SYKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | EGFR 2358/4885MKNK2 490/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.